Want to see KLRS full AI Analyst Report?
Top Page
Kalaris Therapeutics
(NASDAQ:KLRS)
Select Model
Select Model
Rating:44Neutral
Price Target:
$4.50
▼(-28.80% Downside)
Action:Reiterated
Date:07/07/26
The score is primarily constrained by weak financial performance—no revenue, sizable ongoing losses, and heavy cash burn—despite relatively low leverage. Technicals add a mixed signal (short-term stabilization but broader downtrend), while valuation is limited by negative earnings and no dividend. Governance-related corporate events provide a small positive offset.
Positive Factors
Low Financial Leverage
The balance sheet shows low reported debt relative to equity, which reduces near-term insolvency risk and gives management optionality when timing financing rounds. Low leverage is a durable structural cushion for a pre-revenue biotech through development cycles.
Negative Factors
Pre-revenue Status
The company remains pre-revenue with sizable recurring net losses, meaning operations cannot self-finance. This structural profile forces reliance on external capital, increases dilution risk over time, and keeps long-term viability contingent on clinical success or new revenue sources.
Read all positive and negative factors
Positive Factors
Negative Factors
Low Financial Leverage
The balance sheet shows low reported debt relative to equity, which reduces near-term insolvency risk and gives management optionality when timing financing rounds. Low leverage is a durable structural cushion for a pre-revenue biotech through development cycles.
Read all positive factors
Kalaris Therapeutics (KLRS) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$102.81M
Dividend YieldN/A
Average Volume (3M)136.22K
Price to Earnings (P/E)―
Beta (1Y)1.00
Revenue GrowthN/A
EPS Growth73.91%
CountryUS
Employees20
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-2.15
Shares Outstanding23,792,278
10 Day Avg. Volume189,046
30 Day Avg. Volume136,224
Financial Highlights & Ratios
PEG Ratio0.04
Price to Book (P/B)1.63
Price to Sales (P/S)0.00
P/FCF Ratio-2.98
Enterprise Value/Market Cap0.51
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-2.60K
Enterprise Value/Ebitda-1.18
Forecast
1Y Price Target
$18.67Price Target Upside195.36% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering5
EPS Forecast (FY)-2.05
Revenue Forecast (FY)N/A
Kalaris Therapeutics Business Overview & Revenue Model
Company Description
Kalaris Therapeutics Inc. operates as a pharmaceutical enterprise. The company's core mission centers on developing innovative cell therapies. These treatments are designed to reactivate the body's inherent immunity against critical, virus-linked ...
How the Company Makes Money
null...
Kalaris Therapeutics Financial Statement Overview
Summary
Income Statement
14
Very Negative
Balance Sheet
58
Neutral
Cash Flow
22
Negative
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | -20.00K | -13.00K | 0.00 | 0.00 | 0.00 | -1.12M |
| EBITDA | -44.08M | -41.98M | -58.77M | -14.01M | -15.25M | -169.84M |
| Net Income | -44.10M | -43.44M | -58.77M | -14.70M | -15.48M | -171.96M |
Balance Sheet | ||||||
| Total Assets | 109.81M | 121.74M | 118.55M | 3.33M | 3.90M | 286.59M |
| Cash, Cash Equivalents and Short-Term Investments | 97.22M | 117.98M | 118.29M | 3.17M | 3.06M | 248.12M |
| Total Debt | 1.41M | 1.45M | 0.00 | 0.00 | 3.25M | 30.07M |
| Total Liabilities | 41.25M | 42.92M | 5.24M | 48.35M | 34.17M | 61.33M |
| Stockholders Equity | 68.56M | 78.81M | 113.31M | -45.02M | -30.27M | 225.27M |
Cash Flow | ||||||
| Free Cash Flow | -49.09M | -43.18M | -67.70M | -14.13M | -9.78M | -106.34M |
| Operating Cash Flow | -48.88M | -42.98M | -67.70M | -14.13M | -9.78M | -106.32M |
| Investing Cash Flow | -70.07M | -19.72M | 95.00M | 0.00 | 0.00 | 185.98M |
| Financing Cash Flow | 52.42M | 159.61M | 21.00K | 14.24M | 12.78M | 232.00K |
Kalaris Therapeutics Technical Analysis
Negative
6.32
Price Trends
4.77
Negative
6.26
Negative
6.68
Negative
Market Momentum
-0.05
Negative
47.30
Neutral
76.82
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For KLRS, the sentiment is Negative. The current price of 6.32 is above the 20-day moving average (MA) of 4.45, above the 50-day MA of 4.77, and below the 200-day MA of 6.68, indicating a neutral trend. The MACD of -0.05 indicates Negative momentum. The RSI at 47.30 is Neutral, neither overbought nor oversold. The STOCH value of 76.82 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for KLRS.
Kalaris Therapeutics Risk Analysis
Kalaris Therapeutics disclosed 75 risk factors in its most recent earnings report. Kalaris Therapeutics reported the most risks in the "Finance & Corporate" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Kalaris Therapeutics Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
51 Neutral | $2.43B | -8.66 | -87.00% | ― | -36.24% | 11.52% | |
49 Neutral | $2.54B | -9.61 | -253.85% | ― | ― | -15.28% | |
48 Neutral | $254.51M | -1.27 | -174.71% | ― | -76.26% | -9.93% | |
47 Neutral | $69.14M | -1.30 | -127.30% | ― | ― | 49.74% | |
46 Neutral | $219.07M | -4.58 | -80.61% | ― | 43.21% | -15.55% | |
44 Neutral | $102.81M | -2.09 | -72.78% | ― | ― | 73.91% |
* Healthcare Sector Average
KLRS
Kalaris Therapeutics
4.44
2.01
82.72%
CHRS
Coherus Biosciences
1.54
0.66
75.00%
NKTR
Nektar Therapeutics
70.36
45.35
181.33%
CLLS
Cellectis SA
2.99
1.40
88.05%
MCRB
Seres Therapeutics
6.11
-6.46
-51.39%
KOD
Kodiak Sciences
41.31
36.78
811.92%
Kalaris Therapeutics Corporate Events
Executive/Board ChangesRegulatory Filings and Compliance
Kalaris Therapeutics Announces Board and Audit Committee Changes
Positive
Jul 6, 2026
On July 3, 2026, Kalaris Therapeutics announced that director Morana Jovan-Embiricos, Ph.D., resigned from its board and Audit Committee, with the company noting her departure was not due to any disagreement over operations, policies or practices....
Executive/Board ChangesShareholder Meetings
Kalaris Therapeutics Shareholders Back Board, Pay and Auditor
Positive
Jun 4, 2026
At its 2026 Annual Meeting of Stockholders held on June 3, 2026, Kalaris Therapeutics, Inc. stockholders elected Napoleone Ferrara, M.D., David Hallal and Leone Patterson as Class III directors to serve three-year terms expiring at the 2029 annual...
Executive/Board Changes
Kalaris Therapeutics Announces CFO Resignation, Finance Leadership Shift
Neutral
Apr 10, 2026
On April 8, 2026, Kalaris Therapeutics, Inc. disclosed that Chief Financial Officer Matthew Gall had decided to resign from his position, with his departure to take effect on April 14, 2026. The move triggers a leadership transition in the finance...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.